Granpidam

Granpidam is a prescription medication that contains the active ingredient sildenafil, a phosphodiesterase type 5 inhibitor, supplied in an oral dosage form. While the specific strength is not disclosed, the product is marketed within the European Union and is intended for use under medical supervision. Granpidam works by enhancing blood flow in targeted vascular tissues, supporting its approved therapeutic applications and clinical use worldwide.

Granpidam is indicated for specific vascular conditions where increased nitric oxide signaling is beneficial.

- Treatment of erectile dysfunction in adult males. - Management of pulmonary arterial hypertension (PAH) to improve exercise capacity. - Adjunct therapy for certain cases of secondary hypertension associated with endothelial dysfunction. - Off‑label investigation in selected clinical trials for heart failure with preserved ejection fraction. - Use in combination with lifestyle modifications for patients with metabolic syndrome who also experience erectile dysfunction. - Potential benefit in treating Raynaud’s phenomenon when standard therapies are insufficient, based on emerging evidence.

The safety profile of Granpidam reflects the pharmacology of sildenafil, with most patients experiencing mild to moderate reactions.

Common: - Headache, often mild to moderate. - Flushing of the face or neck. - Indigestion or dyspepsia. - Nasal congestion or stuffiness. - Transient visual disturbances, such as a blue‑tinted vision. - Dizziness or light‑headedness. - Back pain or muscle aches.

Serious: - Sudden, unexplained loss of vision (non‑arteritic anterior ischemic optic neuropathy). - Sudden, unexplained loss of hearing. - Priapism – prolonged erection lasting more than four hours. - Severe, symptomatic hypotension, particularly when taken with nitrate medications. - Chest pain or cardiac ischemia.

Before initiating Granpidam, clinicians should evaluate patient history and consider several precautionary factors to minimize risk.

- Known hypersensitivity to sildenafil or any component of the formulation. - History of cardiovascular disease, including recent myocardial infarction or unstable angina. - Concomitant use of nitrate medications for chest pain. - Severe liver impairment or renal dysfunction that may affect drug clearance. - Visual disorders such as retinitis pigmentosa or previous non‑arteritic anterior ischemic optic neuropathy. - Low blood pressure (systolic <90 mm Hg) or uncontrolled hypertension. - Use in patients with certain hereditary retinal conditions.

Granpidam can interact with other medicines, altering its efficacy or safety; some combinations should be avoided while others require careful monitoring.

Avoid: - Nitrate‑containing drugs (e.g., nitroglycerin, isosorbide dinitrate) due to risk of severe hypotension. - Guanylate cyclase stimulators used for pulmonary hypertension (e.g., riociguat). - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) that can markedly increase sildenafil levels.

Use with caution: - Alpha‑blockers (e.g., doxazosin, tamsulosin) – monitor blood pressure. - Other antihypertensive agents – adjust dose if symptomatic hypotension occurs. - CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce therapeutic effect.